MCID: FBR017
MIFTS: 56

Fibrosarcoma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Fibrosarcoma

Aliases & Descriptions for Fibrosarcoma:

Name: Fibrosarcoma 12 50 29 52 42 14 69
Neoplasms, Fibrous Tissue 42 69
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 64 443250000 53654007

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to leukemia and burns. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Tamoxifen and Antineoplastic Agents, Hormonal have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and colon, and related phenotypes are shRNA abundance <= 50% and growth/size/body region

Wikipedia : 71 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
id Related Disease Score Top Affiliating Genes
1 leukemia 29.7 MMP1 MMP2 TIMP1
2 burns 29.4 MMP9 TIMP1 TNF
3 small bowel fibrosarcoma 12.0
4 liver fibrosarcoma 12.0
5 congenital fibrosarcoma 12.0
6 breast fibrosarcoma 11.9
7 fibrosarcoma of bone 11.9
8 adult fibrosarcoma 11.9
9 heart fibrosarcoma 11.8
10 kidney fibrosarcoma 11.8
11 conventional fibrosarcoma 11.8
12 pediatric fibrosarcoma 11.8
13 central nervous system fibrosarcoma 11.8
14 dermatofibrosarcoma protuberans 11.3
15 fibroma 11.2
16 inflammatory myofibroblastic tumor 11.1
17 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.0
18 cerebral sarcoma 10.9
19 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 10.3 ETV6 NTRK3
20 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
21 intracystic papillary adenoma 10.3 ETV6 NTRK3
22 lymphocytic colitis 10.3 MMP2 MMP9 SERPINE1
23 acute tricyclic antidepressant poisoning 10.3 MMP2 MMP9
24 appendix carcinoid tumor 10.3 MMP2 MMP9 TIMP1
25 kleptomania 10.3 MMP1 MMP2 MMP9
26 breast papillary carcinoma 10.2 MMP2 MMP9 TIMP1
27 senile atrophy of choroid 10.2 MMP1 MMP2 MMP9
28 onychocytic matricoma 10.2 MMP1 MMP2 MMP9
29 adenocarcinoma in situ 10.2 MMP14 MMP2 MMP9
30 laryngostenosis 10.2 MMP1 MMP2 MMP9
31 zika fever 10.2 MMP1 MMP2 TIMP1
32 perrault syndrome 10.2 MMP1 SERPINE1 TIMP1
33 xerophthalmia 10.2 MMP1 SERPINE1 TIMP1
34 neuropathy, hereditary sensory, type id 10.2 MMP14 MMP2
35 childhood pleomorphic rhabdomyosarcoma 10.2 MAF MAFB TNF
36 optic nerve neoplasm 10.2 MMP1 MMP9 TIMP1
37 anisomastia 10.2 MMP14 MMP2
38 trichomalacia 10.2 MMP2 MMP9 TNF
39 central nervous system teratoma 10.1 MMP1 MMP2 MMP9 TIMP1
40 linear porokeratosis 10.1 MMP1 MMP14 MMP2 MMP9
41 schwannomatosis 10.1 MMP2 MMP9 TIMP1 TIMP2
42 striated muscle rhabdoid tumor 10.1 MMP2 MMP9 TIMP1 TIMP2
43 traumatic brain injury 10.1 MMP1 MMP14 MMP2 MMP9
44 chordoid meningioma 10.1 MMP9 TIMP1 TNF
45 maxillary neoplasm 10.1 MMP2 MMP9 TIMP1 TIMP2
46 adenoid squamous cell carcinoma 10.1 MMP2 MMP9 TIMP1 TIMP2
47 keratoconus 10.1 PLAU TIMP1 TNF
48 retinal drusen 10.1 MMP2 MMP9 TIMP1 TIMP2
49 adult neuronal ceroid lipofuscinosis 10.1 MMP1 MMP2 MMP9 TIMP2
50 vascular dementia 10.1 MMP2 MMP9 TNF

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 MAFB MAFF MAFG MMP14 MMP2 PLAU

MGI Mouse Phenotypes related to Fibrosarcoma:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 ETV6 JAK1 JUN MAF MAFA MAFG
2 immune system MP:0005387 10.38 MAF MAFB MAFG MAFK MMP1 MMP14
3 cardiovascular system MP:0005385 10.37 MMP14 MMP2 MMP9 NTRK3 PLAU SERPINE1
4 homeostasis/metabolism MP:0005376 10.37 ETV6 MAFA MAFB MMP1 MMP14 MMP2
5 behavior/neurological MP:0005386 10.35 JAK1 JUN MAF MAFB MAFG MAFK
6 hematopoietic system MP:0005397 10.32 ETV6 JAK1 JUN MAFG MAFK MMP14
7 mortality/aging MP:0010768 10.31 MAFG MAFK MMP14 MMP2 MMP9 NTRK3
8 endocrine/exocrine gland MP:0005379 10.19 ETV6 JAK1 JUN MAFA MAFB MMP14
9 nervous system MP:0003631 10.15 JUN MAF MAFB MAFG MAFK MMP14
10 craniofacial MP:0005382 10.09 MMP2 PLAU TNF JAK1 MAF MAFB
11 integument MP:0010771 10.06 SERPINE1 TNF ETV6 JAK1 JUN MAF
12 normal MP:0002873 10.02 MMP14 MMP2 NTRK3 TIMP2 ETV6 JAK1
13 neoplasm MP:0002006 10.01 ETV6 MMP1 MMP2 MMP9 PLAU SERPINE1
14 respiratory system MP:0005388 9.9 JAK1 JUN MAFB MMP14 MMP2 MMP9
15 renal/urinary system MP:0005367 9.8 JAK1 MAF MAFA MAFB MMP14 MMP9
16 skeleton MP:0005390 9.61 JAK1 JUN MAFB MMP14 MMP2 MMP9
17 vision/eye MP:0005391 9.23 JUN MAF MMP14 MMP2 MMP9 NTRK3

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
2 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1
3 Bone Density Conservation Agents Phase 4,Phase 2,Phase 1
4 Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
5 Estrogens Phase 4,Phase 2,Phase 1
6 Hormone Antagonists Phase 4,Phase 2,Phase 1
7 Hormones Phase 4,Phase 2,Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
9 Selective Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
10 Analgesics Phase 4,Phase 2,Phase 1
11 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
14 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Dermatologic Agents Phase 4,Phase 3,Phase 2
17 Efamol Phase 4
18 Estrogen Antagonists Phase 4,Phase 2,Phase 1
19 Hypolipidemic Agents Phase 4
20 Lipid Regulating Agents Phase 4
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Evening Primrose Nutraceutical Phase 4
23
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
24
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
25
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
26
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
27
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
28
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
30
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
31
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
32
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
33
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
34
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
35
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
36
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
37
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
38
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
39
Succinylcholine Approved Phase 3,Phase 1 306-40-1 5314
40
Cyproheptadine Approved Phase 3 129-03-3 2913
41
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
43
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
44
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2 98-92-0 936
45
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
46
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
47 Alkylating Agents Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
50 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 190)
id Name Status NCT ID Phase
1 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4
2 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
3 Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. Active, not recruiting NCT01694654 Phase 4
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
5 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
10 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
11 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
12 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
13 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
15 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
16 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
17 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
18 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
19 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Active, not recruiting NCT02066181 Phase 3
20 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
21 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
22 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
23 Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU Active, not recruiting NCT02139683 Phase 3
24 Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) Active, not recruiting NCT02011919 Phase 2, Phase 3
25 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
27 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3
28 MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas Terminated NCT00147108 Phase 3
29 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
30 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
31 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
32 Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Unknown status NCT02353429 Phase 2
33 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2
34 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
35 Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2
36 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
37 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer Completed NCT00326495 Phase 2
38 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2
39 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
40 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2
41 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
42 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
43 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
44 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
45 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
46 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
47 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
48 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
49 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
50 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

id Genetic test Affiliating Genes
1 Fibrosarcoma 29

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

39
Bone, Breast, Colon, Lung, Heart, Thyroid, T Cells

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 883)
id Title Authors Year
1
Congenital infantile fibrosarcoma mimicking a cutaneous vascular lesion: a case report and review of the literature. ( 27910123 )
2017
2
Gene therapy based on interleukin-12 loaded chitosan nanoparticles in a mouse model of fibrosarcoma. ( 27917281 )
2016
3
Hypercalcemia of Malignancy in a Newborn with Infantile Fibrosarcoma. ( 27128515 )
2016
4
Skull sclerosing epithelioid fibrosarcoma: A case report and review of the literature. ( 27123127 )
2016
5
PRIMARY FIBROSARCOMA OF THE THYROID GLAND: CASE REPORT. ( 27333734 )
2016
6
Sclerosing epithelioid fibrosarcoma. ( 27631873 )
2016
7
Fibrosarcoma of maxilla: A rare case report. ( 27194883 )
2016
8
Mechanistic investigation of toxicity of chromium oxide nanoparticles in murine fibrosarcoma cells. ( 27099490 )
2016
9
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene. ( 27100152 )
2016
10
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. ( 27093299 )
2016
11
Fibrosarcoma of the Gingiva: An Unusual Presentation. ( 27403246 )
2016
12
Sclerosing epithelioid fibrosarcoma with brain metastases. ( 27737533 )
2016
13
Fetal paravertebral congenital fibrosarcoma: MR imaging findings. ( 26711551 )
2016
14
Novel Antitumor Invasive Actions of p-Cymene by Decreasing MMP-9/TIMP-1 Expression Ratio in Human Fibrosarcoma HT-1080 Cells. ( 27476935 )
2016
15
Ameloblastic Fibrosarcoma of the mandible evolving from a prior Ameloblastic Fibroma after two years: an unusual finding. ( 27130840 )
2016
16
Nodular presentation of Dirofilaria repens infection in a cat mimicking a fibrosarcoma. ( 27935633 )
2016
17
Molecular Understanding of Growth Inhibitory Effect from Irradiated to Bystander Tumor Cells in Mouse Fibrosarcoma Tumor Model. ( 27561007 )
2016
18
Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo. ( 26998107 )
2016
19
Biological study of the effect of water soluble [N-(2-hydroxybenzyl)-L-aspartato] gallium complexes on breast carcinoma and fibrosarcoma cells. ( 27484500 )
2016
20
Infantile Fibrosarcoma of Tongue: A Rare Tumor. ( 27398324 )
2016
21
Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways. ( 27035160 )
2016
22
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. ( 26563356 )
2016
23
Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. ( 27256159 )
2016
24
Gelatin promotes murine fibrosarcoma L929 cell detachment and protects the cells from TNFI+-induced cytotoxicity. ( 27031673 )
2016
25
Inhibitory effect of aminoethyl-chitooligosaccharides on invasion of human fibrosarcoma cells. ( 27348727 )
2016
26
Applications of calcium electroporation to effective apoptosis induction in fibrosarcoma cells and stimulation of normal muscle cells. ( 26874618 )
2016
27
Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. ( 27259510 )
2016
28
Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts. ( 26768609 )
2016
29
5-Azacytidine regulates matrix metalloproteinase-9 expression, and the migration and invasion of human fibrosarcoma HT1080 cells via PI3-kinase and ERK1/2 pathways. ( 27573026 )
2016
30
Unusual case of infantile fibrosarcoma evaluated on F-18 fluorodeoxyglucose positron emission tomography-computed tomography. ( 27385891 )
2016
31
Electrochemotherapy increases local control after incomplete excision of a recurring penile fibrosarcoma in a stallion. ( 27995080 )
2016
32
Transformation of Dermatofibrosarcoma Protuberans into a Fibrosarcoma. ( 26955135 )
2016
33
Rare Undifferentiated Tumour of Thyroid: Primary Thyroid Fibrosarcoma. ( 27504356 )
2016
34
A Case Report of an Invasive Infantile Fibrosarcoma of the Forearm. ( 27602180 )
2016
35
V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells. ( 27405779 )
2016
36
Ameloblastic Fibrosarcoma Arising in the Maxilla. ( 27303223 )
2016
37
Corneal fibrosarcoma in a cat. ( 26840792 )
2016
38
Prognosis of Fibrosarcoma in Patients With and Without a History of Radiation for Nasopharyngeal Carcinoma. ( 27654106 )
2016
39
Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study GroupA experience. ( 26849118 )
2016
40
Receptor for hyaluronic acid- mediated motility (RHAMM) regulates HT1080 fibrosarcoma cell proliferation via a I^-catenin/c-myc signaling axis. ( 26825774 )
2016
41
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. ( 25995078 )
2015
42
Type I collagen gel protects murine fibrosarcoma L929 cells from TNFI+-induced cell death. ( 25619136 )
2015
43
Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma. ( 26375879 )
2015
44
Epithelial Dysplasia in Ameloblastic Fibrosarcoma Arising from Recurrent Ameloblastic Fibroma in a 26-Year-Old Iranian Man. ( 26289384 )
2015
45
Post-radiation fibrosarcoma of the cerebrum associated with a prominent, lace-like, perivascular, desmoplastic change. ( 26542334 )
2015
46
Ameloblastic fibrosarcoma of the mandible: a case report and brief review of the literature. ( 25861504 )
2015
47
Primary Pulmonary Fibrosarcoma With Bone Metastasis: a Successful Treatment With Post-Operation Adjuvant Chemotherapy. ( 26413248 )
2015
48
Proa89apoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells. ( 25625225 )
2015
49
Congenital fibrosarcoma in complete remission with Somatostatin, Bromocriptine, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow up. ( 26921571 )
2015
50
Ambiguous effect of signals transmitted by the vagus nerve on fibrosarcoma incidence and survival of tumor-bearing rats. ( 25797182 )
2015

Variations for Fibrosarcoma

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 41)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 JAK1 MAFF MAFG MAFK MMP1 PLAU
2
Show member pathways
12.68 MMP1 MMP14 MMP2 MMP9 SERPINE1 TIMP1
3 12.65 JAK1 JUN MMP1 MMP2 MMP9
4
Show member pathways
12.3 JAK1 JUN MMP1 MMP9 TNF
5 12.27 MMP2 MMP9 PLAU TNF
6
Show member pathways
12.24 JAK1 JUN MMP1 SERPINE1 TIMP1
7 12.21 ETV6 MAF MMP9 PLAU
8 12.15 JAK1 MMP1 MMP14 MMP2 MMP9 TNF
9 12.07 JUN MMP2 MMP9 TNF
10 11.95 MMP14 MMP2 MMP9 SERPINE1
11 11.94 JUN MMP14 MMP9 TNF
12 11.92 JUN MMP14 PLAU SERPINE1
13 11.89 JUN MMP2 SERPINE1 TNF
14 11.86 JAK1 MMP1 MMP2 MMP9 TIMP1 TNF
15 11.82 JUN MMP1 TNF
16 11.8 MMP2 MMP9 TIMP1 TIMP2
17
Show member pathways
11.79 JAK1 JUN TIMP1
18 11.75 JUN MMP2 MMP9
19
Show member pathways
11.75 MMP1 MMP14 MMP2 MMP9 TFPI2 TIMP1
20
Show member pathways
11.73 JUN MAF TNF
21 11.71 MMP1 MMP2 MMP9
22 11.66 JUN MMP14 MMP2 MMP9
23 11.65 JUN MMP2 MMP9
24 11.63 MMP2 MMP9 PLAU TIMP1 TNF
25
Show member pathways
11.6 JUN MMP1 MMP2 MMP9 TNF
26 11.59 JAK1 JUN SERPINE1 TNF
27 11.57 JUN MMP2 PLAU
28 11.53 JAK1 JUN MMP1
29 11.53 JUN MMP2 TNF
30 11.5 JAK1 TIMP1 TNF
31 11.49 MMP2 MMP9 PLAU TNF
32 11.48 JUN MMP9 PLAU
33
Show member pathways
11.45 JUN MMP2 MMP9 PLAU
34 11.39 MMP1 MMP9 TIMP2
35 11.19 JUN MMP1 MMP2 MMP9 PLAU
36 11.15 MMP9 TIMP1 TIMP2
37 11.14 JUN MAF MAFA MAFB MAFF MAFG
38 11.01 MMP1 MMP14 MMP2 MMP9 PLAU SERPINE1
39 11 JAK1 MMP1 TIMP1
40 10.87 JUN MAFG MAFK MMP1
41 10.8 PLAU SERPINE1

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 MMP1 MMP2 MMP9 PLAU SERPINE1 TFPI2
2 extracellular space GO:0005615 9.76 MMP14 MMP2 MMP9 PLAU SERPINE1 TIMP1
3 proteinaceous extracellular matrix GO:0005578 9.43 MMP1 MMP2 MMP9 TFPI2 TIMP1 TIMP2
4 extracellular matrix GO:0031012 9.23 MMP1 MMP14 MMP2 MMP9 SERPINE1 TFPI2

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.97 ETV6 JUN MAF MAFA MAFB MAFF
2 angiogenesis GO:0001525 9.88 JUN MMP14 MMP2 SERPINE1
3 positive regulation of cell migration GO:0030335 9.83 MMP14 MMP9 NTRK3 PLAU
4 response to organic substance GO:0010033 9.78 JUN TIMP1 TNF
5 negative regulation of endopeptidase activity GO:0010951 9.78 SERPINE1 TFPI2 TIMP1 TIMP2
6 circadian rhythm GO:0007623 9.77 JUN NTRK3 SERPINE1
7 ephrin receptor signaling pathway GO:0048013 9.76 MMP2 MMP9 NTRK3
8 negative regulation of peptidase activity GO:0010466 9.76 SERPINE1 TFPI2 TIMP1 TIMP2
9 response to cytokine GO:0034097 9.73 JUN TIMP1 TIMP2
10 response to hormone GO:0009725 9.72 MMP14 TIMP1 TIMP2
11 regulation of cell proliferation GO:0042127 9.72 JAK1 JUN MAFG PLAU TNF
12 blood coagulation GO:0007596 9.65 MAFF MAFG MAFK PLAU TFPI2
13 lens fiber cell differentiation GO:0070306 9.59 MAF NTRK3
14 endodermal cell differentiation GO:0035987 9.58 MMP14 MMP2 MMP9
15 regulation of receptor activity GO:0010469 9.57 PLAU SERPINE1
16 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.54 TIMP1 TIMP2
17 regulation of epidermal cell differentiation GO:0045604 9.43 MAFF MAFG
18 negative regulation of metallopeptidase activity GO:1905049 9.37 TIMP1 TIMP2
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.33 MMP2 MMP9 TNF
20 collagen catabolic process GO:0030574 9.26 MMP1 MMP14 MMP2 MMP9
21 extracellular matrix disassembly GO:0022617 9.1 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
22 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.05 ETV6 JUN MAF MAFA MAFB SERPINE1

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.85 MMP1 MMP14 MMP2 MMP9 PLAU
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.73 ETV6 JUN MAFA MAFB
3 metallopeptidase activity GO:0008237 9.71 MMP1 MMP14 MMP2 MMP9
4 peptidase inhibitor activity GO:0030414 9.67 SERPINE1 TFPI2 TIMP1 TIMP2
5 serine-type endopeptidase activity GO:0004252 9.65 MMP1 MMP14 MMP2 MMP9 PLAU
6 metalloendopeptidase activity GO:0004222 9.62 MMP1 MMP14 MMP2 MMP9
7 transcription factor activity, sequence-specific DNA binding GO:0003700 9.56 ETV6 JUN MAF MAFA MAFB MAFF
8 protease binding GO:0002020 9.46 SERPINE1 TIMP1 TIMP2 TNF
9 sequence-specific DNA binding GO:0043565 9.23 ETV6 JUN MAF MAFA MAFB MAFF

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....